The role of substance use in structural heart disease among women living with HIV.


Journal

Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005

Informations de publication

Date de publication:
19 Dec 2023
Historique:
received: 06 09 2023
accepted: 30 11 2023
medline: 22 12 2023
pubmed: 22 12 2023
entrez: 22 12 2023
Statut: aheadofprint

Résumé

People living with HIV have increased risk of cardiovascular disease, but few studies focus on women with HIV (WWH) and few account for the use of multiple substances. We recruited WWH from San Francisco shelters, free meal programs, street encampments and a safety net HIV clinic. Between 2016 and 2019, participants completed six monthly interviews, specimen collection, and a transthoracic echocardiogram. We assessed associations between three echocardiographic indices of cardiac hypertrophy (concentric hypertrophy, concentric remodeling, and eccentric hypertrophy) and study factors, including cardiovascular risk factors, substance use, and HIV-specific factors (CD4+ count, viral load, HIV medication). Among 62 participants, the average age was 53 years and 70% were ethnic minority women. Just over 70% had elevated blood pressure (BP). Toxicology-confirmed substance use included tobacco (63%), cannabis (52%), cocaine (51%), methamphetamine (29%), and alcohol (26%). Concentric hypertrophy was detected in 26% of participants. It was positively associated with cocaine use (adjusted Relative Risk [aRR]= 32.5, p<0.01) and negatively associated with cannabis use (aRR=0.07, p<0.01). Concentric remodeling was detected in 40% of participants. It was positively associated with cocaine use (aRR=11.2, p<0.01) and negatively associated with cannabis use (aRR=0.17, p=0.02). Eccentric hypertrophy was not significantly associated with factors studied here. Routine evaluation of stimulant use as a contributing factor to cardiovascular risk may improve risk assessment in WWH. Whether cannabis use mitigates the impact of cocaine use on structural heart disease among WWH merits further investigation.

Sections du résumé

BACKGROUND BACKGROUND
People living with HIV have increased risk of cardiovascular disease, but few studies focus on women with HIV (WWH) and few account for the use of multiple substances.
SETTING METHODS
We recruited WWH from San Francisco shelters, free meal programs, street encampments and a safety net HIV clinic.
METHODS METHODS
Between 2016 and 2019, participants completed six monthly interviews, specimen collection, and a transthoracic echocardiogram. We assessed associations between three echocardiographic indices of cardiac hypertrophy (concentric hypertrophy, concentric remodeling, and eccentric hypertrophy) and study factors, including cardiovascular risk factors, substance use, and HIV-specific factors (CD4+ count, viral load, HIV medication).
RESULTS RESULTS
Among 62 participants, the average age was 53 years and 70% were ethnic minority women. Just over 70% had elevated blood pressure (BP). Toxicology-confirmed substance use included tobacco (63%), cannabis (52%), cocaine (51%), methamphetamine (29%), and alcohol (26%). Concentric hypertrophy was detected in 26% of participants. It was positively associated with cocaine use (adjusted Relative Risk [aRR]= 32.5, p<0.01) and negatively associated with cannabis use (aRR=0.07, p<0.01). Concentric remodeling was detected in 40% of participants. It was positively associated with cocaine use (aRR=11.2, p<0.01) and negatively associated with cannabis use (aRR=0.17, p=0.02). Eccentric hypertrophy was not significantly associated with factors studied here.
CONCLUSIONS CONCLUSIONS
Routine evaluation of stimulant use as a contributing factor to cardiovascular risk may improve risk assessment in WWH. Whether cannabis use mitigates the impact of cocaine use on structural heart disease among WWH merits further investigation.

Identifiants

pubmed: 38133589
doi: 10.1097/QAI.0000000000003366
pii: 00126334-990000000-00346
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA037012
Pays : United States
Organisme : NIDA NIH HHS
ID : K24 DA039780
Pays : United States

Informations de copyright

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest and Sources of Funding Outside of grant funding, authors declare no conflicts of interest.

Auteurs

Elise D Riley (ED)

University of California, San Francisco, School of Medicine, Department of Medicine, Division of HIV, Infectious Diseases and Global Medicine, San Francisco, California, USA.

Eric Vittinghoff (E)

University of California, San Francisco, School of Medicine, Department of Epidemiology and Biostatistics, San Francisco, California, USA.

Akshay Ravi (A)

University of California, San Francisco, School of Medicine, Clinical Informatics, San Francisco, California, USA.

Phillip O Coffin (PO)

University of California, San Francisco, School of Medicine, Department of Medicine, Division of HIV, Infectious Diseases and Global Medicine, San Francisco, California, USA.
San Francisco Department of Public Health, San Francisco, California, USA.

Kara Lynch (K)

University of California, San Francisco, School of Medicine, Department of Laboratory Medicine, San Francisco, California, USA.

Alan H B Wu (AHB)

University of California, San Francisco, School of Medicine, Department of Laboratory Medicine, San Francisco, California, USA.

Claudia Martinez (C)

University of Miami, School of Medicine, Department of Medicine, Division of Cardiovascular Medicine, Miami, FL, USA.

Priscilla Y Hsue (PY)

University of California, San Francisco, School of Medicine, Department of Medicine, Division of Cardiology, San Francisco, California, USA.

Classifications MeSH